Background
==========

The publications by Spühler *et al.*\[[@B1]\], Dubach *et al.*\[[@B2]\] and Zollinger \[[@B3]\] five decades ago on the relationship between kidney damage and phenacetin ultimately led to the recognition of a causal relation between the two. This was supported by the experience in the Swedish factory Husqvarna \[[@B4]\]. Many epidemiological studies and review papers contributed to this view. In the 1990ies, many nephrologists by extension suspected that non-phenacetin analgesic combinations, especially those containing paracetamol and aspirin (plus caffeine) might also cause end-stage renal disease (ESRD; cf. reviews \[[@B5]-[@B7]\]), and introduced the term \"analgesic nephropathy.\" Since data were scarce, this hypothesis engendered some controversy \[[@B8],[@B9]\], and ultimately led the regulatory authorities of Germany, Austria and Switzerland to initiate a scientific re-evaluation. A peer review committee of scientists, jointly selected by the regulatory authorities and the pharmaceutical industry, was asked to critically review the data on the relationship between non-phenacetin combined analgesics and nephropathy on the basis of a systematic literature review. The committee\'s three main conclusions were that (1) existing studies show no justified suspicion of any increased risk of ESRD for phenacetin-free analgesic combinations, (2) there is insufficient evidence to associate non-phenacetin combined analgesics with nephropathy and (3) new studies should be done to provide appropriate data to resolve the issue \[[@B10]\].

In their initial deliberations on such a study, the Scientific Board recommended that the outcome of interest be ESRD (defined as incident dialysis), and that the exposure of interest be all phenacetin-free analgesics, including NSAIDs), regardless of the formulation. The board was aware that the analysis would address several subgroups, including analgesics co-formulated with caffeine. The design efforts resulted in a detailed, published study protocol, confirmed and approved by the regulatory authorities \[[@B11]\].

The primary objective of this study was to determine the association between the lifetime use of all phenacetin-free analgesics and the occurrence of ESRD. ESRD risk was to be evaluated for several mono substances (\"Monos\"), fixed combination analgesics (\"Combis\"), by cumulative lifetime dose, duration, and dose by duration of use of phenacetin-free analgesics. This paper presents the main results of the international case-control study on the association of phenacetin-free analgesics and ESRD.

Methods
=======

The study was designed as a population-based case-control study to investigate the risk of phenacetin-free analgesics with regard to the occurrence of ESRD in Germany and Austria between January, 2001 and December, 2004. The study protocol was reviewed and agreed to by the Scientific Advisory Committee, was accepted by the regulatory authorities of Germany, Austria, and Switzerland, and was reviewed and approved by the Kidney Foundation of Germany. It was supported by the three Nephrological Societies in Germany and the Nephrological Association of Austria, published in BMC Nephrology \[[@B11]\], shown on an open-access website \[[@B12]\], registered as clinical study in the FDA website (Protocol Registration Receipt NCT00302835) \[[@B13]\], and approved as a study protocol by the Lancet.

Cases were recruited from 170 dialysis centers and were defined as patients with end-stage renal disease (ESRD) newly admitted to a chronic dialysis program (incident dialysis) and aged up to 50 years. Rapid case ascertainment systems were used to identify all eligible cases. Cases were excluded if they had acute or recurrent renal failure, were out of age range, died before the interview could be done, were in poor physical or mental condition, or refused informed consent to participate in the study. Four neighborhood controls were randomly selected from the same geographic regions as the cases and were matched by age (5-year age group) and sex. Cases and controls documented their willingness to participate in the study by signing an informed consent form.

All study participants completed a standardized in-person interview, during which a trained interviewer collected information on lifetime use of analgesics documented by brand name as well as details and dates of lifetime use, on co-morbidity (renal, circulatory, metabolic, psychiatric, other medical conditions, headache or other painful conditions), treatment history (treatments with potential relation to outcome and risk factors), job exposure (occupation & industrial branch; exposure in selected occupational categories; exposure to groups of certain chemicals and minerals), and other demographic data such as age, sex, area of residence, and health care contacts. Participants were shown a book of color photographs and other descriptions of analgesics (mixed with other common drugs to blind the interviewee) marketed from the 1950s, organized by brand, name, dose, and the period during which the drugs were available to elicit an accurate lifetime history of analgesic use. Training and re-training of interviewers as well as briefing and re-briefing of study centers were standard quality control measures. Detailed logbooks were maintained in all participating dialysis centers for all new dialysis patients. The procedures to minimize potential bias included complete coverage of new dialysis patients (to address selection bias), use of index dates in the analysis (reverse causality bias), blinding of interviewers to the main research question (interviewer bias), and the restriction to phenacetin-free analgesics and adjustment for co-variables to reduce confounding. The data were collected locally, transferred to the central Data Management and Coordination Centre Berlin at the ZEG Berlin, and then to EPES Berlin for data analysis.

The SAC approved a detailed analysis plan for the \"core analyses\" which included a review of center performance and response rates. Frequency distributions of exposure with analgesics by case/control status and by index dates were calculated.

A fixed reference group defined as individuals who had been exposed to less than one table or unit dose of any phenacetin-free analgesic compound per month across *all*12-months periods in their lifetimes was used for all analyses. This group is comprised of all participants who indicated no or very low use of analgesics, and is called \"low use\" in text and tables. This strategy was adopted to account for the potential differential recall of trivial use in cases and controls, based on the notion that controls may have poorer recall of irregular and low use than cases despite all standard memory aids used (cf. protocol published in this journal \[[@B11]\]). The decision was approved by the SAC after discussion of intermediate analyses and became integral part of the analysis plan. All persons suspected to have ever taken phenacetin in their lifetime were excluded.

Several index dates were defined and examined to determine the most appropriate lag time between exposure to analgesics and the start of dialysis. The decision was made that exposures in the 5 years prior to start of dialysis should not be used in analyses concerning ESRD risk \[[@B11]\] because analgesic use may have been initiated due to incipient kidney disease during that time.

Logistic regression analyses were used to estimate the association between ESRD and analgesic exposure. Crude and adjusted odds ratios with 95% confidence interval were calculated. The decision was made a priori to use unmatched analysis if the risk estimates of matched analysis did not materially differ \[[@B11]\]. This is because less information is lost in unmatched analyses and these are therefore better suited for subgroup analyses.

Many possible risk factors for ESRD (cf. Table [1](#T1){ref-type="table"}) were assessed for confounding. Logistic regression with backwards elimination was used to define the adjustment variables for the analytic model. The final set of adjustment variables were age (5-year group), sex (male, female), country (Germany, Austria), first degree family history of chronic renal diseases (yes, no), and self-reported exposure with welding/soldering fumes, solvents (yes, no), and education(over/under 10 years). Following the recommendation of the study\'s statistical advisory committee, co-variables assumed to be intermediates in the causal pathway of ESRD -such as hypertension or diabetes -- were excluded from the list of possible confounders for the final analysis to avoid over-adjustment.

###### 

Characteristics of ESRD cases and controls at study entry.

                                                                                                 Cases^1^N = 907   Controls^1^N = 3622   P             
  ------------------------------------------------------------------------------- -------------- ----------------- --------------------- ------ ------ -----------
                                                                                                 N                 \%                    N      \%     
  Age (years)                                                                     \< 40          424               46.8                  1644   45.4   
                                                                                  40--50         483               53.2                  1978   54.6   .46
  Gender                                                                          Male           585               64.5                  2333   64.4   
                                                                                  Female         322               35.5                  1289   35.6   .96
  Country                                                                         Germany        726               80.0                  2890   79.8   
                                                                                  Austria        181               20.0                  732    20.2   .87
  Education (years)                                                               \- 10          603               66.5                  1998   55.2   
                                                                                  \> 10          304               33.5                  1624   44.8   \< .001
  Smoking                                                                         Never          340               37.5                  1528   42.2   
                                                                                  Current        277               30.5                  694    19.2   
                                                                                  Ex-smoker      290               32.0                  1400   38.6   \< .001
  Alcohol                                                                         Seldom         757               83.5                  1857   51.3   
                                                                                  Often          150               16.5                  1765   48.7   . \< .001
                                                                                                                                                       
  **History of conditions, diseases**                                                                                                                  
  Diabetes mellitus                                                               No             748               82.5                  3572   98.6   
                                                                                  Yes            159               17.5                  50     1.4    \< .001
  Hypertension                                                                    No             134               14.8                  3253   89.8   
                                                                                  Yes            773               85.2                  369    10.2   \< .001
  Renal diseases                                                                  No             25                2.8                   3448   95.2   
                                                                                  Yes            882               97.2                  174    4.8    \< .001
  Urinary tract infections                                                        No             802               88.4                  3478   96.0   
                                                                                  Yes            105               11.6                  144    4.0    \< .001
  Family history: chronic renal disease                                           No             697               76.9                  3425   94.6   
                                                                                  Yes            210               23.1                  197    5.4    \< .001
  Migraine                                                                        No             766               84.5                  3250   89.7   
                                                                                  Yes            141               15.5                  372    10.3   \< .001
  Headache                                                                        No             656               72.3                  2728   75.3   
                                                                                  Yes            251               27.7                  894    24.7   .06
  Menstruation problems                                                           No             233               25.7                  937    25.9   
                                                                                  Yes            89                9.8                   352    9.7    
                                                                                  n.a.           585               64.5                  2333   64.4   .99
  Arthritic complaints                                                            No             828               91.3                  3418   94.4   
                                                                                  Yes            79                8.7                   204    5.6    \< .001
  Chronic back pain                                                               No             710               78.3                  2866   79.1   
                                                                                  Yes            197               21.7                  756    20.9   .58
  Psychological/neurological problems                                             No             829               91.4                  3397   93.8   
                                                                                  Yes            78                8.6                   225    6.2    .01
                                                                                                                                                       
  **History of treatment**                                                                                                                             
  Anti-rheumatic treatment                                                        No             892               98.4                  3600   99.4   
                                                                                  Yes            15                1.6                   22     0.6    \< .01
  Immuno-suppressive therapy                                                      No             866               95.5                  3617   99.9   
                                                                                  Yes            41                4.5                   5      0.1    \< .001
  Drug treatment against cancer                                                   No             889               98.0                  3605   99.5   
                                                                                  Yes            18                2.0                   17     0.5    \< .001
  Long-term treatment with antibiotics                                            No             854               94.2                  3526   97.4   
                                                                                  Yes            53                5.8                   96     2.7    .000
                                                                                                                                                       
  **Complaints**(subjectively compared with other persons in the same age span)                                                                        
  Gastrointestinal problems                                                       No, rare       577               63.6                  2550   70.4   
                                                                                  Similar/more   330               36.4                  1072   29.6   \< .001
  Cardiovascular problems                                                         No, rare       610               67.3                  3041   84.0   
                                                                                  Similar/more   297               32.7                  581    16.0   \< .001
  Vomiting                                                                        No, rare       612               67.5                  3187   88.0   
                                                                                  Similar/more   295               32.5                  435    12.0   \< .001
  Depression                                                                      No, rare       719               79.3                  3172   87.6   
                                                                                  Similar/more   188               20.7                  450    12.4   \< .001
  Anxiety                                                                         No, rare       762               84.0                  3259   90.0   
                                                                                  Similar/more   145               16.0                  363    10.0   \< .001
  Sleeplessness                                                                   No, rare       542               59.8                  2821   77.9   
                                                                                  Similar/more   365               40.2                  801    22.1   \< .001
  Fatigue                                                                         No, rare       333               36.7                  2490   68.8   
                                                                                  Similar/more   574               63.3                  1132   31.2   \< .001
  Irritability                                                                    No, rare       505               55.7                  2376   65.6   
                                                                                  Similar/more   402               44.3                  1246   34.4   \< .001
  Stress                                                                          No, rare       459               50.6                  1713   47.3   
                                                                                  Similar/more   448               49.4                  1909   52.7   \< .001
  Eating problems                                                                 No, rare       752               82.9                  3368   93.0   
                                                                                  Similar/more   155               17.1                  254    7.0    \< .001
                                                                                                                                                       
  **History of exposures at work site**                                                                                                                
  Heavy metal                                                                     No             750               82.7                  3216   88.8   
                                                                                  Yes            157               17.3                  406    11.2   \< .001
  Other metal dust                                                                No             765               84.3                  3240   89.5   
                                                                                  Yes            142               15.7                  382    10.5   \< .001
  Special silicates^2^                                                            No             847               93.4                  3431   94.7   
                                                                                  Yes            60                6.6                   191    5.3    .11
  Other silicates^3^                                                              No             796               87.8                  3375   93.2   
                                                                                  Yes            111               12.2                  247    6.8    \< .001
  Solvents                                                                        No             751               82.8                  3188   88.0   
                                                                                  Yes            156               17.2                  434    12.0   \< .001
  Welding & soldering fumes                                                       No             797               87.9                  3384   93.4   
                                                                                  Yes            110               12.1                  238    6.6    \< .001

^1^Deviations from the total number of cases and controls are due to missing information

^2^e.g. quartz, silicon dioxide, fibre glass, silicone

^3^e.g. sand, cement, coal, grain dust

The analyses focused on the association between high cumulative lifetime dose (grams) and ESRD across various subgroups of analgesic formulations. The primary comparison was that of the top tertile of cumulative lifetime dose with no or very low use for users of all phenacetin-free analgesics and for users of analgesic subgroups.

Due to the small numbers in many analgesic formulation subgroups, the SAC recommended using only a minimum of adjustment variables and to refrain from calculating or reporting odds ratios if any of the cells for a comparison contained less than 10 subjects. Doses per duration of use were analyzed as well as dose-response analyses. More detailed dose-response analyses will be published at a later time in a methodology paper. Because matched and unmatched analyses showed virtually identical results, the SAC decided that this publication should show the results of unmatched analyses.

All statistical analyses were performed with the commercial statistical software Stata 8.1.

Results
=======

Description of cases and controls
---------------------------------

Of 1,831 cases identified, 1,305 met the study entry criteria, 978 were interviewed, and 907 phenacetin-free cases were included in the analysis. The reasons for exclusion are shown in Figure [1](#F1){ref-type="fig"}. Similarly, of 6,587 potential neighborhood -controls, 6.236 were eligible, 3,892 were interviewed after 1,878 were excluded due to refusal to participate and 466 for undeclared reasons, and 3,622 controls without history of phenacetin use finally entered the analysis (Fig. [1](#F1){ref-type="fig"}). There were 71 cases and 270 controls with reasonable evidence for past phenacetin use mainly during childhood or early youth who were excluded from analysis. In terms of the study protocol, response rates of 74.9% for cases (978 of 1,305 eligibles) and 62.4 % (3,892 interviewed of 6,236 eligible) were considered acceptable. No important heterogeneity was observed for response rates across subgroups of age, gender, or case/control status (data not shown).

![Flow chart: inclusion and exclusion of possible cases and controls.](1471-2369-8-15-1){#F1}

Table [1](#T1){ref-type="table"} provides an overview of baseline characteristics for all cases and their controls. As expected from the matching process, there was no difference between cases and controls with regard to age, sex, and country. Compared with cases, controls had a proportionately higher educational level (defined as more than 10 years of school), smoked less, but consumed more alcohol. Cases more frequently reported conditions suspected to play a role in ESRD development such as diabetes, hypertension, renal diseases, urinary tract infections, and a first-degree family history of chronic renal conditions. There was a higher proportion of painful conditions such as headache, migraine, chronic back or arthritic pain as well as use of specific medications (anti-rheumatic, immune-suppressive, or long-term therapy with antibiotics) among cases than among controls. Relative to their age group, controls more frequently voiced minor subjective physical and psychological complaints than did cases, which were more prone to major complaints (Table [1](#T1){ref-type="table"}). Cases more often reported worksite exposure to heavy metals, other metal dust (such as aluminum, copper, chromium, tin), certain silicates (such as sand, cement, coal, rock, grain dust), solvents (such as varnish & paints, glue, crude oil, fuel, diesel, toluene), and welding and soldering fumes. These descriptive differences were taken into account for the determination of the adjustment factors for the main analysis.

The most frequently named underlying conditions leading to ESRD were glomerulonephritis (34.5%), pyelonephritis/interstitial nephritis (7.6%), polycystic kidney disease (12%), and diabetic nephropathy (15.8%), Other diseases such as lupus erythematosus, tuberculosis, vasculopathy, infarction, alport syndrome, and amyloid nephrosis were named in 18.5% of cases. The cause of kidney disease was unclear for the treating physician in 10.9%. \"Analgesic nephropathy\" was considered to be the cause of ESRD in only 5 of 907 cases (0.6%).

Overall risk of ESRD, ever use, and cumulative lifetime dose
------------------------------------------------------------

The main research question defined in the study protocol addressed the risk of ever use of phenacetin-free analgesics at index date 3 (the status 5 years before first dialysis) compared with no or low use of such substances. This standard reference group of individuals with no or very low use was defined as including those with exposure to less than one tablet or unit of any phenacetin-free analgesic compound per month across *all*12-months periods of the participant\'s lifetime. The adjusted odds ratio (OR) for this analysis is 0.84, 95% confidence interval (CI): 0.71 to 0.98. The crude and adjusted risk estimates were virtually identical.

The association between cumulative lifetime dose of analgesics and ESRD is shown in Table [2](#T2){ref-type="table"}. The sub-categories of lifetime analgesic use are *not*mutually exclusive. The use of higher cumulative lifetime dose (tertile 3) of analgesics up to five years before dialysis was not associated with later ESRD either for all phenacetin-free analgesics together (All), or for analgesics with a single substance (monos), or for analgesics with multiple components (combis). Most risk estimates were below unity (1.0). Risk estimates calculated for medium lifetime doses (= tertile 2 and 1 combined) compared with the reference group of low use showed significantly decreased estimates. The adjusted comparison of high users of all phenacetin-free analgesics together with no or very low use showed a risk of 1.02 (95% CI: 0.81 to 1.28), the same estimate for all mono-analgesics was 0.98 (95% CI: 0.77 to 1.24). This estimate did not change when aspirin and paracetamol were excluded from the mono-preparations (OR 0.90; 95% CI: 0.61 to 1.31.). The overall estimate for the ESRD risk of high use of any combination analgesic compared with the reference group of no or very low use was 1.05 (95% CI: 0.77 to 1.44). Combination analgesics with or without paracetamol showed risk estimates in the same order of magnitude (cf. Table [2](#T2){ref-type="table"}). Finally, no differences were found for the comparison between high versus low use when examining compounds with and without caffeine in this younger population with no prior use of phenacetin. We observed no evidence of an increased or different risk of ESRD associated with analgesic use (all analgesics, single substances, or combination products) with regard to the underlying disease of ESRD. The risk varied around unity across all disease subgroups containing sufficient numbers for analysis. These data will be presented at a later time in a clinical publication.

###### 

Lifetime dose of analgesic use^1^and risk of ESRD.

                                         Exposure      Range grams   Cases   Controls   Adjusted OR^2^(95% CI)
  -------------------------------------- ------------- ------------- ------- ---------- ------------------------
  All phenacetin-free analgesics         Low                         546     2030       1.0 (referent)
                                         Tertile 1,2   \< 217        213     1067       0.75 (0.63--0.90)
                                         Tertile 3     \> = 217      148     525        1.02 (0.81--1.28)
  **[MONOS]{.ul}**(single substance)     Tertile 1,2   \< 185        185     975        0.72 (0.59--0.87)
  All monos                              Tertile 3     \> = 185      129     479        0.98 (0.77--1.24)
                                         Other                       47      138        1.21 (0.84--1.74)
  All- no ASA & paracetamol              Tertile 1,2   \< 65         62      322        0.70 (0.51--0.94)
                                         Tertile 3     \> = 65       43      159        0.90 (0.61--1.31)
                                         Other                       256     1111       0.87 (0.73--1.03)
  **[COMBIS]{.ul}**(combined products)                                                  
  All combis together                    Tertile 1,2   \< 91         93      469        0.73 (0.56--0.93)
                                         Tertile 3     \> = 91       75      235        1.05 (0.77--1.44)
                                         Other                       193     888        0.84 (0.69--1.02)
  All combis with paracetamol            Tertile 1,2   \< 83         87      401        0,78 (0.59--1.01)
                                         Tertile 3     \> = 83       57      197        0.95 (0.67--1.35)
                                         Other                       217     994        0.84 (0.70--1.01)
  All combis without paracetamol         Tertile 1,2   \< 68         27      131        0.75 (0.49--1.16)
                                         Tertile 3     \> = 68       26      64         1.41 (0.85--2.35)
                                         Other                       308     1397       0.82 (0.69--0.97)
  All combis with caffeine               Tertile 1,2   \< 87         67      342        0.70 (0.52--0.94)
                                         Tertile 3     \> = 87       55      169        1.01 (0.71--1.44)
                                         Other                       239     1081       0.85 (0.71--1.02)
  All combis without caffeine            Tertile 1,2   \< 57         44      237        0.69 (0.49--0.99)
                                         Tertile 3     \> = 57       37      118        1.15 (0.76--1.73)
                                         Other                       280     1237       0.84 (0.70--0.99)

^1^Lifetime dose of analgesic use: medium = tertile1 and 2; high = tertile 3 vs. referent = no or very low analgesic use (exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across *all*12-months periods in the observed lifetime) at index date 3 (5 years before first dialysis). The category \"other\" means: other analgesics than those considered in the specific sub-analysis. The numbers don\'t add up because participants were classified into the category \"other\" analgesic, which is not exclusive.

^2^Unmatched analysis; adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Adjustment for age group, sex, country, family history chronic renal diseases, exposure with welding/soldering fumes, solvents, and education

Combined association of dose and duration
-----------------------------------------

The relationship of analgesic dose and duration of use and their potential impact on ESRD development was examined extensively. Table [3](#T3){ref-type="table"} shows the analyses for all analgesics, mono-substance and combination preparations separately for lower and higher user of analgesics and for shorter and longer durations, where the cut-off points for each class are based on the respective median value found in controls. Although no significant increase is found, the table indicates that there may be a weak positive association with higher doses of analgesics used for shorter duration (left lower corner of Table [3](#T3){ref-type="table"}) On the other hand, lower user of analgesics for longer durations (upper right corner) showed statistically significant lower risks for 2 of 3 analgesic types analyzed. Finally, lower use and shorter duration showed a statistically significant inverse association for all 3 analgesic types. There was an inverse association (not statistically significant) for 2 of 3 types for higher dose and longer duration of use. The numbers were too small for stable risk estimates of formulation subgroups.

###### 

Dose and duration of analgesic use and risk of ESRD: All analgesics.

                                           **Short duration**   **Long Duration**             
  --------------- ------------------------ -------------------- ------------------- --------- -------------------
  **Low dose**    All analgesics           123/580              0.78 (0.63--0.97)   36/216    0.62 (0.43--0.89)
                  All monos together^1^    106/529              0.74 (0.59--0.93)   31/200    0.57 (0.39--0.85)
                  All combis together^2^   49/264               0.69 (0.50--0.95)   19/84     0.84 (0.51--1.40)
  **High Dose**   All analgesics           70/214               1.21 (0.91--1.61)   132/582   0.84(0.67--1.05)
                  All monos together^1^    60/194               1.14 (0.84--1.55)   117/531   0.82(0.65--1.03)
                  All combis together^2^   29/88                1.22 (0.79--1.88)   71/268    0.99 (0.74--1.33)

^1^Cases and controls that never used mono-analgesics were not shown in this table (47 cases, 138 controls for the group \"all monos\"

^2^Cases and controls that never used combination-analgesics were not shown in this table (193 cases, 888 controls for the group \"all combis\"

Unmatched analysis; index date 3 (5 years before start of dialysis); *adjusted*odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age, sex, country.

The cut-off point for higher/lower use and shorter/longer duration is the respective median found in controls; compared with the standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across *all*12-months periods in the observed lifetime) as referent (= 1.0): 546 cases and 2030 controls.

Adjustment for confounding by other analgesic formulations
----------------------------------------------------------

In order to account for overlapping of the use of different analgesic formulation during the participant\'s lifetime, all other analgesic subgroups were taken into the equation (Table [4](#T4){ref-type="table"}). No significant association with ESRD was shown for any formulations containing ASA, paracetamol or containing neither of these two substances, i.e. the ESRD risk associated with high use (3^rd^tertile of cumulated lifetime use) vs. low use varied around unity.

###### 

Risk of ESRD and cumulative lifetime dose of Paracetamol, ASA, and substances containing neither ASA nor Paracetamol (mainly Ibuprofen) in any combination (mono- or combi) versus low use^1^

                Dose (tertiles)   Range (grams)   Cases   Controls   OR (95% CI)
  ------------- ----------------- --------------- ------- ---------- -------------------
  No/rare use                                     546     2030       1.0 (referent)
  ASA           I                 \< 50           96      431        0.96 (0.60--1.54)
                II                50--162         77      443        0.77 (0.46--1.27)
                III               163+            114     432        1.07 (0.64--1.77)
  Paracetamol   I                 \< 17           61      297        n.d.^2^
                II                17--74          65      304        0.95 (0.63--1.42)
                III               75+             77      296        1.11 (0.74--1.67)
  Other         I                 \< 12           38      208        0.66 (0.41--1.08)
                II                12--73          47      215        0.79 (0.50--1.23)
                III               74+             63      209        n.d.^2^

^1^Standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across *all*12-months periods in the observed lifetime. Unmatched analysis; Adjustment for family history, soldering fumes, solvents, education, and for age, sex, country. Adjustment for confounding by all other analgesic combinations.

^2^dropped due to collinearity

n.d. = no data

Dose-response
-------------

The cumulative lifetime dose of analgesics (in grams) was stratified in eight sub-categories in steps of 500 grams up to 3.5 kg in order to show the risk distribution up to the uppermost dose groups (Table [5](#T5){ref-type="table"}). There was no increased risk for ESRD up to 3.5 kg cumulative lifetime dose (98 % of the cases with ESRD). A significantly increased risk was found for the tiny subgroup of upper-most lifetime dose of more than 3.5 kg in this young age group (19 cases and 11 controls, 2% of all cases and 0.3% of all controls). Conversely, the risk was significantly reduced for the large subgroup of user with a lifetime dose up to 0.5 kg. In a second approach we examined the risk of ESRD contributed per gram at various levels of use compared with \"no or very low use\". This essentially confirms the above mentioned results, as each gram of use is associated with lowered risk for the group below 0.6 kg lifetime analgesics consumption, it is associated with no risk in the group up to 4.6 kg, and only in the group over 4.6 kg is there a significantly increased risk of ESRD per dose (table not shown). This threshold applies to 12 cases (= 1.3% of all cases) and 3 controls (= 0.08%) in this study. None of these were categorized as analgesic nephropathy by their treating physicians.

###### 

Adjusted relative risk of ESRD by increasing cumulative lifetime dose of analgesic use (all analgesics together).

  Grams        Cases   Controls   OR (95% CI)
  ------------ ------- ---------- --------------------
  Low use      546     2030       1.00 (referent)
  -500         278     1365       0.75 (0.64--0.88)
  501--1000    41      133        1.10 (0.77--1.59)
  1001--1500   10      47         0.76 (0.38--1.52)
  1501--2000   6       19         1.03 (0.40--2.62)
  2001--2500   4       9          1.50 (0.48--4.74)
  2501--3000   3       8          1.35 (0.37--4.94)
  3001 +       19      11         6.02 (2.83--12.81)

Categorical modeling for dose-response analyses. Odds ratios and 95% confidence intervals. Analysis based on index date 3 (5 years before start of dialysis), adjusted for age, sex, country. ORs were not calculated if the frequency in any group was less than 10 per cell: no data (n.d.) in the table. Standard reference group of low use is defined as exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across *all*12-months periods in the observed lifetime.

Description of pattern associated with uppermost cumulative lifetime use of analgesics
--------------------------------------------------------------------------------------

A detailed review of the characteristics of the 22 cases (2.4 % of all cases) and 19 controls (0.5 % of all controls) who reported at least 2.5 kg or more cumulative lifetime dose of analgesics was conducted. This cut-off point was recommended by the SAC and approved by the German Drug Authority. No difference in the reason for analgesic use for the cases and controls in this subgroup, or in their subjective complaints was determined. However, conditions associated with the causal pathway of ESRD such as hypertension, diabetes, gout, arterial diseases (cardiac, cerebral, peripheral), renal diseases, other serious diseases or operations, and family history of chronic renal diseases were much more prevalent in cases than in controls with upper-most, extreme use of analgesics. Cumulatively, 70% of the 22 cases had three and more of these seven conditions and 70% of the 19 controls had 0--1 of these conditions related to the evolution of ESRD (Table [6](#T6){ref-type="table"}).

###### 

Number of factors related to development of ESRD in individual cases and controls with high-end intake of analgesics (see table before).

  Number of conditions^1^   Cases n = 22          Controls n = 19   
  ------------------------- -------------- ------ ----------------- ------
                            n              \%     n                 \%
  **6**                     1              4.5    0                 0
  **5**                     4              18.2   0                 0
  **4**                     6              27.3   0                 0
  **3**                     5              22.7   0                 0
  **2**                     5              22.7   6                 31.6
  **1**                     1              4.5    7                 36.8
  **0**                     0              0      6                 31.6

^1^The following seven conditions were considered for this table: Arterial problems (coronary, brain, peripheral), hypertension, diabetes mellitus, gout, renal diseases, other serious diseases/operations, and family history of chronic renal diseases (first degree relatives)

Discussion
==========

The objective of this study was the investigation of the effect of lifetime use of phenacetin-free analgesics on ESRD occurrence in a younger population. The restriction to a study group below the age of 50 was a prerequisite for the effective exclusion of phenacetin use, and we believe that this is the first study to completely avoid phenacetin contamination in the assessment of ESRD associated with analgesic uses. The results suggest that there is no association between ESRD and analgesic use in general, nor with the use of specific analgesics or combinations with or without additional caffeine in the age group below 50 years.

The direct comparison of baseline users of no or very low lifetime analgesic doses with the tertile distributions of lifetime doses in grams of the user group shows no increased ESRD risk associated with phenacetin-free analgesics in the highest tertile. Instead, there was a significantly reduced risk ESRD for the lower two tertiles for all analgesics, mono-preparations, and combination products. No clinically relevant increase of ESRD risk with increasing dose was found in an analysis of the effect of ASA, paracetamol, and other ingredients with full adjustment including other analgesic combinations. Users of lower doses of analgesics showed a decreased risk of ESRD independent of duration of use (Table [3](#T3){ref-type="table"}). The group of users of high lifetime doses showed a non-significant tendency for higher risks when these substances were taken within a shorter period. We cannot draw any strong conclusions from the findings related to the combined associations of dose and duration of analgesic use.

The detailed examination of dose-response distributions showed no association or significantly reduced risks of ESRD for almost all levels of analgesic use. However, a tiny group of cases and controls showed a significantly increased risk associated with a dose over 3.5 kg in the dose-stratified analyses. This was found to significantly increase around a dose of 4--5 kg lifetime use of analgesics in the continuous dose analyses. This level of use corresponds to a daily consumption of 200 to 400 grams of analgesic over a 30-year period. Because the numbers in this subgroup were too low for estimation, a detailed description was prepared for this upper-most dose group (22 cases and 19 controls). The main distinction between cases and controls were the much higher prevalence of factors closely associated with later development of ESRD among the cases, so that we interpret this group as being defined by their high-risk status rather than by their use of analgesics which is incidental to their prior health condition. The same conclusion was reached by an external expert in nephrology (Prof. Michielsen) who was asked by the Scientific Advisory Committee of the study and by the German Drug Authority to individually evaluate the likelihood that high analgesic use in these cases is is the cause of their ESRD. Prof. Michielsen expressed in his report that the individual assessment of lifetime users of 2.5 kg analgesic user indicated:1)There is no evidence of classical analgesic nephropathy, and 2) that there is no indication that analgesic use influenced the evolution to ESRD in this small group of extremely high users (cf. full assessment report at the SAN website \[[@B12]\]).

Strengths and weaknesses of the study
-------------------------------------

The two important advantages of this study are the use of a 5-year lag-time across all analyses on analgesic exposure and ESRD risk and the presumably complete exclusion of past use of phenacetin. The 5-year lag time has previously been used in only two \[[@B14],[@B15]\] studies. It addresses the issue of temporality and reduces the risk of showing estimates based on analgesic use prompted by an incipient renal condition rather than on the occurrence of a renal condition following a period of analgesic use (reverse causality bias). To our knowledge, no previous study has eliminated phenacetin use from its population to the extent this study has, and we consider this a condition sine qua non for the estimation of ESRD risk associated with the currently available analgesics.

Every effort was made to minimize recall and information bias by using face-to-face interviews with a set of aids and procedures to jog memory, check the plausibility of recalled analgesic use, and to provide similar conditions for cases and controls. Selection bias is addressed in the community-based approach of this case-control study. Logbooks were maintained in dialysis centers to assure complete coverage. Nonetheless, and although comparable with other studies in this area, a non-response rate of around 30% leaves some possibility for bias. It is reassuring that the information available on non-responders did not differ from the information for those included in the study. Finally, the study suffers the limitations of all observational studies in that the participation of cases may be very much determined by intentions of the treating physician who invited patients, while the situation could differ for controls. Differences in reporting behavior between cases and controls can never be entirely excluded, and controls who consumed large amounts of analgesics may have a poor health-related quality of life which prevents them from volunteering for such a study.

The age limit of 50 years is strength of the study because it largely eliminates phenacetin users from this population, but it may also restrict the generalizability of the findings. However, this study feature was considered an essential safeguard against confounding by phenacetin use. Reliable results for the risk of ESRD and analgesic use in the population aged 50 to 70 years, for example, could be obtained only in the decades when phenacetin users had slowly depleted. Even then, the much higher potential of serious confounding and bias in the higher age group would make it difficult to interpret an association because, if any association is found, it is likely to be small. Although the possibility that some persons might not have sufficient time to accumulate a harmful lifetime dose up to the age of 50 years, we consider the evidence of no clinically important association between analgesic use and ESRD provided by this study to be the best currently available. Therefore, and in the absence of other reliable evidence, the results of this study most likely also apply to higher age groups.

The debate on analgesic use and nephropathy has gone on for decades and is not yet concluded \[[@B16]\]. Many earlier studies which did not exclude past phenacetin use found a significant association between analgesic use and chronic renal failure/ESRD with relative risk increases ranging from 2- to 8-fold \[[@B17]-[@B22]\]. Other studies observed no or no clearly increased risk or variations among formulations \[[@B14],[@B15],[@B23],[@B24]\] or else were inconclusive \[[@B25],[@B26]\]. Fored *et al.* (2003) \[[@B15]\] did not rule out that the associations found in their study might be due to bias, i.e. that the use of analgesics was triggered by conditions associated with the renal disease.

Recently, Mihatsch *et al.* (2006) \[[@B27]\], conducted an exact replication of the benchmark autopsy studies on analgesic nephropathy which he performed 1978--80 in Basel \[[@B28]\]. The author wrote: \"The last and single autopsy case of proven classic analgesic nephropathy detected only with the present sophisticated histological study at the end of the year 2000 can thus be taken as further evidence that this type of chronic renal disease was due to nothing but phenacetin-containing mixed analgesics. Some 20 years after removal of phenacetin from the market classic analgesic nephropathy is all but disappearing and will no longer be a health hazard in the 21^st^century.\" \[[@B27]\]. The results of the present study on a population of individuals with no prior phenacetin use supports this finding.

The present study adds to the available data characterizing the association of ESRD risk and lifetime consumption of analgesics applying advanced methods. Our data show no significant association between ESRD and analgesic use in general or for the use of specific analgesics or combinations with or without additional caffeine. The descriptive analysis of a small highly exposed subgroup indicates that their very high cumulative lifetime use of analgesics is based on a pattern of chronic, painful ill health and does not constitute a causal association with ESRD. However, further research on extreme users of analgesics is recommended.

Conclusion
==========

We found no clinically meaningful evidence for an increased risk of ESRD associated with use of phenacetin-free analgesics in single or combined formulation. The apparent risk increase shown in a small subgroup with extreme lifetime dose of analgesics is most likely an indirect, non-causal association. This hypothesis, however, cannot be confirmed or refuted within our case-control study. Overall, our results lend support to the mounting evidence that phenacetin-free analgesics do not induce ESRD and that the notion of \"analgesic nephropathy\" needs to be re-evaluated.
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